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Natriuretic peptides (NP) activate particulate guanylate cyclase (pGC) and nitric oxide (NO) activates soluble guanylate cyclase (sGC).
Both guanylate cyclases catalyse the formation of the same second messenger, cyclic guanosine 3V,5V-monophosphate (cGMP), which
activates the cGMP-dependent protein kinases (PKG). PKG then starts a signalling cascade that mediates many cardiovascular and renal
effects, such as smooth muscle relaxation and diuresis. Many cell types possess both sGC and pGC. Because both GC-cGMP systems play
complementary roles, an interaction between the two pathways might represent an important physiological control mechanism. In this report
we demonstrate an interaction between the two pathways. C-type natriuretic peptide (CNP) decreased the h-subunit of sGC (sGC-h) steady-
state protein levels and enzymatic activity in cultured human mesangial cells (HMC) in a time- and dose-dependent manner. This down-
regulation was not dependent on changes in sGC-h mRNA levels. Treatment of the cells with the stable cGMP analogue 8-Br-cGMP or the
phosphodiesterase type-5 inhibitor Zaprinast produced the same down-regulatory effect. Inhibition of PKG or proteasome activity prevented
the CNP-induced reduction of sGC-h protein levels and activity. Taken together, these results demonstrate that pGC activation induces a
post-transductional down-regulation of sGC by a mechanism involving PKG and the proteasome pathway.
D 2003 Elsevier B.V. All rights reserved.Keywords: Soluble guanylate cyclase; Particulate guanylate cyclase; Cross-regulation; Protein degradation; Proteasome; cGMP
1. Introduction (CNP) [4]. CNP and pGC-B comprise a vascular natriureticVascular tone is determined by the balance between
vasodilators such as nitric oxide (NO), natriuretic peptides
(NP), and prostacyclin and vasoconstrictors such as endo-
thelin-1 and angiotensin II [1]. NO and NP initiate multifac-
eted actions that reduce vascular tone, inhibit platelet
aggregation, and promote natriuresis and diuresis [2,3]. NP
activates particulate guanylate cyclase (pGC) and NO acti-
vates soluble guanylate cyclase (sGC). The pGC is a homo-
dimeric transmembrane receptor and the type B isoform
(pGC-B) is activated by the C-type natriuretic peptide0167-4889/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamcr.2003.10.003
* Corresponding author. Department of Physiology, Medicine Faculty,
Universidad de Alcala´, Crta. Madrid-Barcelona Km 33.600, Alcala´ de
Henares, E-28871 Madrid, Spain. Tel.: +34-91-885-4519; fax: +34-91-880-
4590.
E-mail address: manuel.rodriguez@uah.es (M. Rodriguez-Puyol).peptide paracrine system with ligand and receptor being
expressed in endothelial and smooth muscle cells, respec-
tively [5]. The sGC is a cytoplasmic heterodimeric hemo-
protein that is composed of two different subunits, a and h.
The main sGC isoform, widely expressed in human tissues,
is a1h1 [6].
Both GCs catalyse the formation of cyclic guanosine 3V,5V-
monophosphate (cGMP). The cellular concentration of
cGMP is determined by both GC activity and phosphodies-
terase (PDE) activity, especially PDE type-5 (PDE-5) [7].
cGMP, acting as a second messenger, activates cGMP-
dependent protein kinases (PKG) which initiate a protein
phosphorylation cascade that mediates the physiological
response [8]. Both GC pathways have feedback regulation.
NO-sGC is regulated by the concentration of NO, possibly
through a cGMP-dependent pathway [9–11]. NP-pGC also
incorporates a self-regulating mechanism [12–15].
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serve complementary functions [16]. Thus, the two pathways
probably interact to regulate cGMP levels. Previous reports
showed such an interaction, but the observed effects appear
to be species- and tissue-specific. NO donors have been
reported to increase [17,18], decrease [19], or have no effect
[20–22] on the response of blood vessels to ANP, a CNP-
related peptide that activates pGC-type A. A lack of effect is
also observed in airway smooth muscle cells in culture [23].
Similarly, ANP has been reported to both increase [24] and
decrease [25,26] the activity of the NO-sGC pathway in
cultured cells. A recent report demonstrated that both GCs
cooperatively regulate cGMP-mediated vasorelaxation in
human vascular tissue and in eNOS knockout mice that lack
endogenous endothelial-derived NO production [27]. In the
same murine model, Gyurko et al. [28] demonstrated an up-
regulation of prepro-ANP mRNA expression.
The molecular mechanism by which such cross-regula-
tion occurs has not been completely elucidated. In this paper
we report a functional interaction between pGC and sGC by
analysing the effect of CNP on the levels of the h-subunit of
sGC (sGC-h) in cultured human mesangial cells (HMC). We
show that CNP decreases sGC-h protein levels and activity
by a cGMP-dependent mechanism. This reduction is
achieved, at least in part, through increased degradation of
sGC-h by proteosomes and occurs without changes in sGC-
h mRNA expression.2. Materials and methods
2.1. Materials
CNP, 8-bromoguanosine 3V,5V-cyclic-monophosphate, the
antagonist of PKG type I Rp-8-[(4-chlorophenyl)thio]-
cGMPs triethylamine (Rp-cGMPs), sodium nitroprusside
(SNP), anti-h-tubulin antibody, isobutylmethylxanthine
(IBMX), triethanolamine-HCl (TEA), dithiothreitol, GTP,
phosphocreatine, creatine kinase, phenylmethylsulfonyl
fluoride (PMSF), leupeptin, pepstatin A, aprotinin, ammo-
nium persulfate, Triton X-100 and ponceau red were pur-
chased from Sigma Chemical (St. Louis, MO, USA).
Zaprinast was provided by May & Baker Ltd (Dagenham,
England). B136 pGC antibody was kindly provided by
Suntory Co. (Osaka, Japan). sGC-h antibody and Z-LLF-
CHO proteasome inhibitor were purchased from Calbiochem
(La Jolla, CA, USA). Spermine NONOate (spNO) was
provided by Alexis Biochemicals (Carlsbad, CA, USA),
Peroxidase-conjugated goat anti-rabbit Ig was purchased
from Chemicon (Temecula, CA, USA). RPMI 1640, foetal
calf serum, trypsin-EDTA (0.02%) and penicillin-streptomy-
cin were purchased from Bio Media (Boussens, France). a-
[32P]-dCTP, RediPrime radiolabelling system, nitrocellulose
membrane, G-Sepharose beads, low and high molecular
weight standards were purchased from Amersham-Pharma-
cia (Piscataway, NJ, USA). BCA protein assay reagent waspurchased from Pierce (Rockford, IL, USA). [35S]-methio-
nine/cysteine was provided by Applied Biosystems (Foster
City, CA, USA). All the other reagents were of the highest
commercially available grade.
2.2. Cell culture
HMC were cultured in RPMI medium containing 10%
foetal bovine serum according to previously described
procedures [29]. When cells reached confluence, they were
subcultured at a ratio of 1:4, using the same incubation
medium. The identity of the cells was confirmed by mor-
phological and functional criteria, as previously described
[30]. Experiments were performed in passages 3–5. When
the cells reached 100% confluence, they were serum-de-
prived for 24 h before the treatments.
2.3. Protein extraction and Western blot analysis
Following treatment, HMC were washed briefly in PBS
and solubilized in lysis buffer (10 mM Tris–HCl pH 7.4, 1
mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate,
500 nM sodium orthovanadate, 50 nM NaF, 1 Ag/ml
pepstatin/ leupeptin/aprotinin, 1 mM phenylmethtylsulfonyl
fluoride) for 40 min at 4 jC. Protein concentration was
determined using the BCA method as recommended by the
manufacturers.
To perform Western blot analysis, total cell extracts (30
Ag/lane) were size-fractionated by SDS-PAGE on 7.5%
polyacrylamide gels and transferred in 20% methanol to
polyvinylidene difluoride membranes (Perkin Elmer, Bos-
ton, MA, USA). Ponceau red staining was used to verify
equal loading of membranes. The membranes were blocked
with Tris-buffered (50 mM) saline solution (pH 7.6) with
0.05% Tween (TBS-T) containing 5% milk powder at room
temperature for 1 h. The membranes were incubated with a
1:5000 dilution of a rabbit polyclonal antibody against sGC-
h, washed and incubated with a peroxidase-conjugated goat
anti-rabbit Ig. The presence of sGC (h) was detected using
the SuperSignal system (Pierce) and autoradiography. The
films were then scanned and analyzed using appropriate
software (NIH Image 1.55 from the National Institutes of
Health, Bethesda, MD, USA).
Linearity of sGC-h immunodetection procedure was
demonstrated by performing a standard curve with serial
dilutions of cellular protein extracts (3.75 to 200 Ag of
protein). The optical density of each standard protein was
then plotted against its concentration, and regression analysis
was used to calculate the concentration of GCs/Ag of total
cell lysate. At least two different gels containing increasing
concentrations of total cell lysate were analysed, obtaining a
linear curve between concentration and optical density
(r2>0.9). To ensure linearity, multiple exposures of each blot
were always evaluated. In some experiments, the blots were
stripped and reblotted against h-tubulin antibody to assure
that GCs protein changes were specific.
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HMC were homogenized using guanidinium isothiocya-
nate, and total RNA was isolated by repeated phenol–
chloroform extractions and isopropanol precipitation as
described [31]. Total RNA (10 Ag per lane) was denatured
by heating in formamide/formaldehyde at 65 jC for 5 min
and electrophoresed through a 1% agarose gel containing
0.66 M formaldehyde. To confirm the quantity and quality of
total RNA, the 18 S ribosomal RNA concentration in each
lane was quantified in the ethidium bromide-stained gels.
The RNA was transferred to a nitrocellulose membrane and
UV-cross-linked. The membranes were prehybridized at 42
jC for 24 h in 5 SSPE (0.75 M NaCl, 0.05 M NaPO4H2, 6
mM EDTA, pH 8), 5 Denhardt’s solution (0.1% ficoll,
0.1% polyvinylpyrrolidone, 0.1% bovine serum albumin,
5% formamide, 0.5% SDS) and 0.1 mg/ml denatured salmon
sperm DNA. The membranes were hybridized at 60 jC in
hybridization solution (10% dextran sulfate, 1% SDS, 1 M
NaCl, 0.1 mg/ml denatured salmon sperm DNA) with
a-33[P]-dCTP 106 cpm/ml of radiolabelled sGC cDNA
probe. A 408-bp cDNA fragment of sGC was obtained by
RT-PCR from HMC total RNA using the following primers
based on the human sGC-h1 sequence [32] (forward, base
position 350 5V-CGTGTCCTGGGCTCTAA-3V and reverse,
base position 774 5V-ACCACTAGGTCCCGGTC-3V). The
nucleotide sequence was determined to confirm that no
errors had been introduced by PCR amplification. Mem-
branes were washed twice for 5 min each in 2 SSC (0.3 M
NaCl, 0.03 M sodium citrate, pH 7.0) and 0.5% SDS at 42
jC. Autoradiography was performed at  80 jC for 24–48
h. Densitometric analysis of the exposed films was per-
formed with a scanner and analysed using NIH Image 1.55
software.
2.5. sGC activity assay
The enzimatic assay was performed as described previ-
ously [33] with slight modifications. In brief, cells were
scrapped in 1 ml of Hanks’ balanced salt solution (HBSS;
Gibco-BRL, Gaithersburg, MD), and pelleted at 10,000 g
for 30 s. The pellet was resuspended in 100 Al of homoge-
nization buffer consisting of 100 mM triethanolamine-HCl
(TEA), 5 mM MnCl2, 1.25 mM IBMX, 10 Ag/ml leupeptin,
10 Ag/ml pepstatin A, 1 mM PMSF, pH 7.4. Samples were
homogenized by sonication and centrifuged at 10,000 g
for 10 min at 4C. The cytosolic fraction was obtained by
centrifuging the supernatant fraction at 100,000 g for 1 h at
4 jC. Assays for sGC activity were conducted in a final
volume of 50 Al consisting of 40-Al aliquots of each sample
and 5 Al of a co-factor solution consisting of 1 M TEA, 50
mM MnCl2, 20 mM dithiothreitol, 1 mM GTP, 50 mM
phosphocreatine, 1520 U/l creatine kinase, 10 mM IBMX,
80 Ag/ml leupeptin, 80 Ag/ml pepstatin A, 8 mM PMSF at
pH 7.4. The reaction was started with 5 Al of 10 mM SNP or
S. de Frutos et al. / Biochimica etsolvent alone (control). After 15 min at 37C, assays were
terminated by adding 0.9 ml of 50 mM sodium acetate
buffer, pH 4.0, and heated for 3 min at 90 jC. cGMP levels
were measured using a commercial [125I]-cGMP radioim-
munoassay kit (Amersham, Arlington Heights, IL).
2.6. Measurement of cGMP synthesized by sGC in HMC
Control and CNP-treated confluent cells were washed
three times with buffer A (Tris 20 mM, NaCl 130 mM, KCl 5
mM, sodium acetate 10 mM, glucose 5 mM, pH 7.45). Cells
were then preincubated with the same buffer containing 2.5
mM Ca2 + and IBMX 10 4 M. Reactions were started with
the addition of NO (spNO 10 6 M) for 30 min. The medium
was aspirated and 1 ml of ice-cold ethanol was added to the
plates, which were maintained at 4 jC for 30 min. Cell
extracts were centrifuged for 20 min at 2000 g and the
supernatant fraction was evaporated to dryness. cGMP levels
were determined with the use of a commercial [125I]-cGMP
radioimmunoassay kit. Protein concentration in the pellets
was determined according to the Bradford method.
2.7. Pulse and chase labelling with [35S]-methionine/
cysteine
For metabolic labelling with [35S]-methionine/cysteine,
cells were incubated in methionine- and cysteine-free
DMEM to deplete intracellular pools. They were then pulsed
for 2 h with methionine/cysteine-free DMEM containing 25
ACi/ml of [35S]-methionine/cysteine. After the pulse period,
the cells were washed with chase medium (serum-free
RPMI), and incubated as detailed below. The incubation
medium was then removed, and the cells were scraped off at
the indicated time points (0–24 h). The proteins were
immunoprecipitated as described below and electrophoresed
in a SDS-PAGE gel. Subsequently the dehydrated gels were
exposed to autoradiography film.
2.8. Immunoprecipitation and immunoblot analysis
Cell cultures were chilled on ice and washed three times
with cold PBS supplemented with 0.2 mM vanadate. Sub-
sequently the culture dishes were incubated for 30 min with
0.7-ml RIPA lysis buffer (150 mM NaCl, 1% Triton X-100,
1% sodium deoxycholate, 0.1% SDS, 50 mM tris–ClH pH
7.2, 1 mM PMSF and 0.2 mM sodium vanadate). The
resulting solution was spun down (12,000 rpm for 30 min
at 4 jC). The protein concentration in each lysate was
determined as described. For each immunoprecipitation,
300 Ag of extracted cell proteins was used. Incubations with
sGC-h antibody were performed overnight at 4 jC with
gentle agitation. The antigen–antibody complexes were
preabsorbed with 30 Al of swollen protein G-sepharose for
1 h at 4 jC. The beads were pelleted and washed five times
with RIPA-buffer. The immunocomplexes were solubilized
by boiling in 15 Al of 5 Laemmli sample buffer (0.1 M tris,
Fig. 1. Effect of CNP treatment on sGC-h protein steady-state levels. (A)
Western blot analysis showed that a significant reduction of sGC-h
occurred at 8 and 24 h in the presence of 10 6 M CNP. (B) The reduction
of sGC-h levels at 24 h was dose-dependent. Protein levels of the
constitutive protein as h-tubulin did not change. Levels are expressed as
percent of control (C), which was assigned a value of 100%. Insets (A) and
(B): typical Western blots. n= 6, *P< 0.05 vs. control.
Fig. 3. Effect of CNP treatment on sGC-h mRNA levels. (A) 10 6 M CNP
did not alter sGC-h mRNA levels during 24 h of exposure. (B) 10 8–10 6
M CNP did not alter sGC-h mRNA levels after 24 h of exposure. Levels
were normalized to 18S RNA content and expressed as percent corrected
versus control (C), which was assigned a value of 100%. Insets (A) and (B):
typical Northern blots. n= 6.
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nol blue indicator) and analysed by SDS-PAGE under
reducing conditions.Fig. 2. Effect of CNP treatment on sGC-h activity. 10 6 M CNP decreased
sGC-h activity during 24 h of exposure. Extracted sGC from control cells
(C ) or cells treated with CNP (CNP) for 24 h were activated with SNP
10 6 M (NO, hatched bars) or not (basal, open bars). cGMP levels
produced were expressed as percent of control (C, open bar), which was
assigned a value of 100%. Inset: typical radioimmunoanalized cGMP
levels; n= 6.
Fig. 4. CNP down-regulation of sGC-h requires pGC activity. Treatment
with a specific blocking antibody against pGC (ab-pGC, 5 Ag/ml) for 24 h
had no effect on sGC-h levels. However, it prevented the sGC-h down-
regulation induced by CNP. Inset: typical Western blot. C, control; n= 6,
*P< 0.05 vs. control.
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Each experiment was repeated at least three times in
duplicate. The data are expressed as meansF S.E. Compar-
isons were made by analysis of variance followed by Dun-
nett’s modification of the t-test whenever comparisons were
followed by a common control. The unpaired two-tailed
Student’s test was used for other comparisons. The level of
statistically significant difference was defined as P < 0.05.
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3.1. CNP decreases sGC protein levels by a pGC/cGMP/
pKG-dependent pathway
To demonstrate a possible cross-regulation of GC, HMC
were treated with CNP, the agonist of pGC, for 0 to 24 h.Fig. 5. Both 8-Br-cGMP- and non-CNP-dependent increases of cGMP
mimic CNP down-regulation of sGC-h. (A) The stable cGMP analogue 8-Br-
cGMP (10 6 M) mimicked the effect of CNP-produced cGMP on sGC-h
levels during 24 h of exposure. Inhibition of PDE-dependent hydrolysis of
cGMP with IBMX (IBMX, 10 6 M) (B) or Zaprinast (Z, 10 6 M) (C) also
mimicked CNP-dependent down-regulation of sGC-h levels. No added re-
duction was achieved with the combination of Zaprinast and CNP. Insets (A),
(B) and (C ): typical Western blots. C, control; n= 6, *P < 0.05 vs. control.
for 24 h with a specific inhibitor of PKG-I (PKG-inhibitor, 25 10 6 M)
alone had no effect on sGC-h levels. However, it inhibited the CNP-
induced sGC-h reduction. Inset: typical Western blot. C, control; n= 6,
*P < 0.05 vs. control.Steady-state sGC protein levels were determined by West-
ern blot using specific sGC-h antibody. CNP decreased the
sGC protein levels in a time-dependent manner (Fig. 1A).
The decrease was dependent on the concentration of CNP,
reaching a maximum effect at 10 6 M and 24 h of
treatment (Fig. 1B). Therefore, this dose and time were
used subsequently to study the regulation of sGC-h steady-
state levels.
The next step was to clarify if the CNP treatment could
also inhibit the enzyme activity. Thus, we performed a sGC
enzyme assay in cells treated with CNP 10 6 M for 24 h,
extracting the soluble fraction of the cells, which was acti-
vated with NO (SNP 10 6 M as NO donor) or vehicle (basal)
for 15 min, and determining the cGMP levels produced by
RIA. sGC activity in CNP-treated cells decreased (Fig. 2) in
parallel with the decrease in sGC protein levels.
We next performed Northern blot analysis for specific
sGC-h mRNA to determine if the inhibitory effect of CNP
was due to differences in mRNA expression. No changes in
the sGC-h mRNA levels occurred up to 24 h (Fig. 3A) or
with any concentration of CNP up to 10 6 M (Fig. 3B).
To clarify the mechanism involved in this sGC down-
regulation, we co-treated the cells with a specific pGC-
blocking antibody (5 Ag/ml) and 10 6 M CNP. The anti-
body itself had no effect on sGC-h levels (Fig. 4). However,
it did abrogate CNP reduction of sGC-h protein steady-state
levels (Fig. 4). Thus, the reduction of sGC-h levels in
response to CNP required the activity of the natural NP
receptor, pGC.
A soluble cGMP analogue, 8-Br-cGMP (10 5 M),
mimicked the CNP effects on the sGC-h levels (Fig. 5A).
Furthermore, treatment with a general PDE inhibitor
(IBMX, 10 6 M) and the specific PDE-5 inhibitor Zapri-
Fig. 7. Time-dependent loss of newly synthesized sGC-h. HMC were pulse-
labelled with [35S]-methionine/cysteine for 2 h. After the washout period,
cells were incubated with 10 6 M CNP and harvested at the times indicated.
CNP significantly increased the loss of sGC-h at 24 h. Undegraded sGC-h
levels are expressed as percent of the control (time = 0 h) value. Inset:
typical autoradiographs of immunoprecipitates from control and CNP-
treated cells. n= 6, *P < 0.05 vs. control.
Table 1
Effect of PI-II on cGMP production by CNP-treated cells
Treatment cGMP (%)a
Control 100
Control +NO 264F 12
CNP-treated +NO 147F 11b
CNP-treated +NO+PI-II 278F 18
a NO-stimulated values are meanF S.E.; n= 5.
b P < 0.05 vs. other NO-stimulated cells.
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Taken together, these results show that the down-regulatory
effect of CNP is dependent on pGC activation and cGMP
production.
We next looked at the participation of PKG, the main
kinase activated by cGMP. Rp-cGMPs (25 10 6 M), a
PKG type I specific inhibitor, prevented the CNP-induced
decrease in sGC-h protein levels (Fig. 6). Thus, PKGFig. 8. CNP-induced reduction of sGC-h levels requires proteasome
activity. HMC were incubated with the specific proteasome inhibitor 10 5
M PI-II for 24 h. PI-II alone did not alter sGC-h levels. However, it did
inhibit the CNP-induced down-regulation while protein levels of the
constitutive protein h-tubulin did not change. Inset: typical Western blot. C,
control; n= 6, *P< 0.05 vs. control.activity mediates the sGC-h down-regulation elicited by
CNP-pGC activation.
3.2. CNP-stimulated decrease of sGC-b requires protea-
some activity
The observation that CNP reduced sGC-h protein levels
without a change in sGC-h mRNA expression prompted us
to investigate the stability of sGC. After pulse labelling for 2
h with 35S-methionine/cysteine, immunoprecipitated la-
belled-sGC-h from untreated cells decreased over time,
and 25 + 5% was lost in control cells after 24 h of chase
(Fig. 7). After 24 h of CNP treatment, 70 + 5% of the
labelled-sGC-h protein was lost, indicating a more rapid
degradation induced by CNP.
To study the mechanism of sGC-h degradation, we
treated the cultures with the cell-permeable proteasome
inhibitor, Z-LLF-CHO (PI-II, 10 5 M). PI-II prevented
the CNP effect on sGC-h protein steady-state levels (Fig.
8). Protein levels of the constitutive protein h-tubulin did
not change on PI-II-treated cells. Thus, cGMP released
after pGC activation by CNP reduced the level of sGC-h
by a specific mechanism dependent on the proteasome
pathway.
To confirm this result, the effect of NO (SNP or spNO
10 6 M as NO donors, 15 min) on cGMP synthesis was
tested in cultured cells pretreated with vehicle (control) or
CNP (10 6 M, 24 h), with or without PI-II (10 5 M).
cGMP levels were measured by RIA. CNP blunted the
significant stimulation cGMP production induced by NO
in control cells (Table 1). Proteasome inhibition by PI-II
prevented this down-regulation.4. Discussion
Our results clearly show that CNP decreased the levels
of sGC-h protein and enzymatic activity, but this effect is
not dependent on changes of sGC-h mRNA expression.
Blocking pGC activity with a specific antibody prevented
the reduction of sGC steady-state levels by CNP. The pGC
blocking antibody used here (B136, kindly provided by
Suntory) is a competitive and selective antagonist for the
CNP receptor, and its neutralizing efficiency has been
described [34]. The inhibitory effect of CNP was mim-
icked by 8-Br-cGMP, a cell-permeable analogue of cGMP
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These results are further supported by the prevention of
native cGMP degradation by inhibition of PDE-5 with
Zaprinast.
In endothelial, mesangial and smooth muscle cells, PKG
type I (PKG-I ) begins the biochemical cascade in which
selected serine and threonine residues on target proteins are
phosphorylated [35–37]. The specific antagonist for PKG-
I, Rp-cGMPs, blocked the CNP-stimulated down-regula-
tion of sGC protein levels. Thus, the down-regulatory
effect is mediated by PKG in response to cGMP produced
by pGC.
Dephosphorylation has been implicated as the mecha-
nism of sGC desensitisation in the sea urchin and in
mammals [38]. Ferrero et al. [39] showed that PKG indi-
rectly inhibits sGC activity through dephosphorylation in
bovine chromaffin cells, and pretreatment with CNP
decreases the activity of sGC. One of the target proteins
of PKG-I is PDE-5, the major enzyme that degrades cGMP
in vivo and in vitro [40,41]. Thus, activation of PDE-5 by
PKG-I may provide negative feedback regulation of the
sGC/cGMP signalling pathway. While our results are com-
patible with the possibility that PKG activates PDE by
phosphorylation, we clearly show here that in cultured
HMC, CNP regulates the absolute levels of sGC.
The down-regulation of sGC levels was achieved
through CNP promotion of proteasome activity. Protea-
somes are large multisubunit proteases that are found in
the cytosol. They recognize, unfold and digest protein
substrates that have been marked for degradation by the
attachment of a ubiquitin moiety [42]. Blockage of protea-
some activity with PI-II, a cell-permeable, irreversible
inhibitor of the proteasomes [43], inhibited the accelerated
rate of protein degradation induced by CNP. This effect was
specific for sGC, because the constitutive protein h-tubulin
was not changed by the proteasome activation. Indeed, the
cGMP levels produced in NO-stimulated cells previously
treated with CNP and PI-II were increased almost two times
compared to NO-stimulated cells treated with CNP alone,
where the increase in cGMP levels due to NO stimulation
was inhibited by the down-regulation of sGC. Mason et al.
[44] demonstrated that phosphorylated proteasomes have
significantly higher activities when compared to non-phos-
phorylated ones in rat fibroblasts. Therefore, CNP-activated
PKG could start a phosphorylation cascade leading to
increased proteasome activity.
Because both GC-cGMP systems have complementary
roles to play, an interaction between the two pathways to
regulate cGMP levels might represent an important physi-
ological control mechanism. In this way, an excess or
deficiency in one mediator could be compensated by the
other. Conversely, the interaction may constitute a negative-
feedback system that prevents overactivation of cGMP
signaling in one cell type by NO and/or NP. Our results
support this hypothesis, but it remains to be determined if
NO down-regulates pGC levels or activity.Acknowledgements
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